Six attorneys from Rivkin Radler will be speakers at USLAW Network’s virtual retreat, which takes place September 30 through October 9. The retreat is intended for general counsel, in-house counsel, heads and managers of claims and risk, C-suite executives, and other legal decision makers.

The program will cover issues beyond COVID-19, projecting what the future

Brian Bank, Michelle Bholan and Geoffrey Kaiser secured pre-answer dismissal of various False Claims Act claims brought against three New York nephrologists by a relator, also a nephrologist.

The action, which the relator brought on behalf of the United States of America under the False Claims Act’s qui tam provisions, alleged two theories against the

Jeff Kaiser was quoted in Part B News, “Do Stark waivers cover your rent break? Only if the break meets ‘COVID-19 purposes.”

The article discusses the new Stark Law waivers issued due to the COVID-19 pandemic. One waiver in particular covers rental arrangements that are under fair market value (FMV) which are normally forbidden under

Marc Ullman was interviewed for the Natural Products Insider article, “FDA, supplement manufacturer debate NDI import alert request.”

The article discusses why the FDA should issue an import alert on beta-alanine ingredients manufactured in China.

To read the full article, click here.

On August 27, Marc Ullman will be presenting at the American Herbal Products Association (AHPA) Hemp-CBD Supplement Virtual Congress. The seminar will provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market.

Click here to register.

Eric Fader, Jeff Kaiser, Chris Kutner, Ada Kozicz and Ben Malerba are authors of the newly released book, “The Federal Anti-Kickback Statute and Safe Harbors: A Practical Guide.”

Published by the American Bar Association, the book covers all safe harbors currently in place, as well as the interplay between the Anti-Kickback Statute (AKS) and other

Marc Ullman spoke with Vitamin Retailer about the repercussions of the Coronavirus pandemic on the natural products industry. He was joined by 11 other panelists representing manufacturers, industry associations and consultants to the industry.

To read the Q&A click here.

Marc Ullman was quoted in a Nutraingredients-USA.com article entitled “Warning letter cites CBD’s regulatory status as leading issue.”

The Food and Drug Administration sent a warning letter to a supplement manufacturer regarding various failures in good manufacturing practice (GMP). For the first time, however, the letter cited the health claims made about CBD as the first

Marc Ullman was quoted in the Nutraingredients-USA.com article, “NPA calls for FDA to issue import alerts on imported adulterated dietary supplement ingredients.”

The Natural Products Association is requesting that the Food and Drug Administration deal with the import of nutritional supplements that fail to comply with New Dietary Ingredient (NDI) regulations. Marc noted that FDA has

Robert Iseman spoke to Part B News about how medical practices should take steps to protect themselves from legal and insurance issues.

The article, “Assess legal risk, payer policies to head off hidden dangers of COVID-19 reopening,” advises medical practices that are beginning to reopen on preparations they can make to be ready for any